Marketing-authorisation holder · United States
Medexus Pharma, Inc.
8 medicines in 1 country, as authorisation holder.
Group structure
Part of
MedexusPharmaceutical groupOther companies in the group
Canada1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine in the registers under its name, current ones first.
8 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| GRAFAPEX1gm/vial | 5gm/vial · Powder | Treosulfan | United States | Marketed | 2025 |
| Ixinity2000iu · For Injection | Coagulation factor ix | United States | Not marketed | 2015 |
| Ixinity1000iu · For Injection | Coagulation factor ix | United States | Marketed | 2015 |
| Ixinity250iu · For Injection | Coagulation factor ix | United States | Not marketed | 2015 |
| Ixinity3000iu · For Injection | Coagulation factor ix | United States | Marketed | 2015 |
| Ixinity500iu · For Injection | Coagulation factor ix | United States | Not marketed | 2015 |
| Ixinity1500iu · For Injection | Coagulation factor ix | United States | Marketed | 2015 |
| RASUVO10mg/0.20ml (10mg/0.20ml) | 12.5mg/0.25ml (12.5mg/0.25ml) | 15mg/0.30ml (15mg/0.30ml) | 17.5mg/0.35ml (17.5mg/0.35ml) | 20mg/0.4ml (20mg/0.4ml) | 22.5mg/0.45ml (22.5mg/0.45ml) | 25mg/0.5ml (25mg/0.5ml) | 27.5mg/0.55ml (27.5mg/0.55ml) | 30mg/0.6ml (30mg/0.6ml) | 7.5mg/0.15ml (7.5mg/0.15ml) · Solution | Methotrexate | United States | Marketed | 2014 |